The company's main activities are research, development, production and sale of original products, generic and active pharmaceutical ingredients.
Grindeks specializes in the therapeutic groups of cardiovascular, central nervous system, anticancer drugs and gastroenterological agents.
Grindeks Group consists of 4 subsidiaries in Latvia, Estonia and Slovakia; representations are open in 11 countries.
Products are exported to 77 countries and account for 92.5% of total turnover. The most important markets are the countries of the European Union, Russia and other CIS countries, the USA, Canada, Japan and Vietnam.
Grindeks shares are listed on the Official List of the Nasdaq Riga Stock Exchange.
They care about public health, motivation of their employees and interests of shareholders. They are an innovation-based and environmentally friendly company.
They want to become a pharmaceutical company of European interest.
Employees - we are professionals who use their knowledge and skills to achieve their goal.
Quality - we are responsible for safe and effective medicines, ecologically clean environment and work safety.
Creativity - we are driving the development of science and research and introducing the latest technologies.
Stability - we are reliable partners, socially responsible and respectful of traditions.See more